Drug Trial Radar · NCT01728805
Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL
Last checked: Nov 20, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
372
Actual
Start
Nov 2012
Primary completion
Mar 2017
Study completion Feb 17, 2021
Sponsor
- Lead sponsor
- Kyowa Kirin, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 20, 2012
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the progression free survival of KW-0761 versus vorinostat for subjects with relapsed or refractory CTCL.
Conditions
- Cutaneous T-Cell Lymphoma
Interventions
KW-0761Biological
1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
VorinostatDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free SurvivalTime frame: From date of randomization at every visit until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months
Locations
73 sites in 11 countries. Site status is shown where the registry gives one.
University of Alabama - Birmingham
Birmingham, Alabama
Banner MD Anderson
Gilbert, Arizona
City of Hope National Medical Center
Duarte, California
UCLA Medical Center
Los Angeles, California
Stanford Medical Center
Stanford, California
University of Colorado
Aurora, Colorado
Yale University School of Medicine - Yale Cancer Center
New Haven, Connecticut
H. Lee Moffitt Cancer Center
Tampa, Florida
The Winship Cancer Institute (Emory University)
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Indiana University
Indianapolis, Indiana
University of Kansas Cancer Center
Westwood, Kansas
Tulane University Medical Center
New Orleans, Louisiana
Massachusetts General Hospital
Boston, Massachusetts
Boston Medical Center, Department of Medicine, Section of Hem/Onc
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Washington University School of Medicine
St Louis, Missouri
Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire
Universal Dermatology, PLLC
Fairport, New York
Columbia Presbyterian
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
University of Rochester School of Medicine
Rochester, New York
Wake Forest Baptist Medical Center
Winston-Salem, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Ohio State University
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
Thomas Jefferson University
Philadelphia, Pennsylvania
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
M.D.Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute
Salt Lake City, Utah
University of Washington
Seattle, Washington
Medical College of Wisconsin
Milwaukee, Wisconsin
Westmead Hospital
Westmead, New South Wales, Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia
Flinders Medical Centre
Bedford Park, South Australia, Australia
Parkville Cancer Clinical Trials Unit
Melbourne, Victoria, Australia
Aarhus University Hospital
Aarhus, Denmark
CHU de Nantes
Nantes, France
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.